Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
The CYBN news page on Stock Titan provides an archive of news releases and updates related to Cybin Inc., a Phase 3 clinical-stage neuropsychiatry and pharmaceutical company focused on developing next-generation treatment options for mental health conditions. These news items come directly from the company’s public communications and are also referenced in its Form 6-K filings with the U.S. Securities and Exchange Commission.
Readers can find coverage of Cybin’s clinical development programs, including updates on its lead candidates CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder, and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. News releases describe milestones such as trial enrollment progress, regulatory approvals to initiate studies in various countries, and participation in healthcare and investor conferences.
The news feed also includes information on Cybin’s capital markets activity, such as registered direct offerings of common shares and pre-funded warrants, the establishment and use of an at-the-market equity program, and the company’s stated intentions for the use of proceeds, including repayment of convertible debentures and funding of its clinical programs. Corporate updates, including plans to transfer its U.S. stock exchange listing from the NYSE American to the Nasdaq Global Market and the associated change in ticker symbol from CYBN to HELP, are documented in detail.
Because Cybin files many of these news releases as exhibits to Form 6-K, the CYBN news page serves as a convenient way to follow the narrative of its clinical progress, financing decisions, and listing changes over time. Investors and researchers can use this archive to review how the company describes its strategy in neuropsychiatry, its geographic operations in Canada, the United States, the United Kingdom, and Ireland, and its stated commitment to rigorous scientific research and regulatory compliance for its investigational compounds.
Cybin, a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present at two investor conferences on September 30, 2021. The conferences are the Cantor Virtual Global Healthcare Conference at 2:00 PM ET and the Benzinga Healthcare Small Cap Conference at 12:15 PM ET, followed by a panel discussion on mental health therapies. Both events will be available via live webcast. Cybin is dedicated to advancing psychedelic drug development for psychiatric disorders, employing innovative drug discovery and delivery techniques.
Cybin, a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The presentation will be available on-demand starting at 7:00 AM ET and can be accessed for 90 days via the provided link. As a leader in psychedelic therapeutics, Cybin employs innovative drug discovery platforms and treatment regimens aimed at psychiatric disorders. However, all forward-looking statements are subject to risks and uncertainties.
Cybin Inc. (NYSE AMERICAN:CYBN) announced that its subsidiary, Adelia Therapeutics, has met certain milestones for Year 1 Q3 as per a December 4, 2020 agreement. In recognition, 9,392.6 Class B shares will be issued to Adelia shareholders, valued at approximately
Cybin (NEO:CYBN, AMERICAN:CYBN), a biotechnology company, has filed two international patent applications under the Patent Cooperation Treaty (PCT), potentially covering 153 countries. These applications pertain to a library of phenethylamine compounds and novel psychedelic compounds identified through research. The patents aim to strengthen the CYB005 program addressing therapy-resistant psychiatric disorders. Cybin’s drug development focuses on novel drug discovery, efficient delivery systems, and treatment regimens targeting mental health needs, including major depressive disorder and alcohol use disorder.
Cybin Inc. (NEO:CYBN) announced the filing of a new non-provisional patent application following a favorable international search report for its May 2021 PCT application. The International Patent Searching authority has validated claims within the filing, which supports the company’s pre-clinical and research programs. Cybin's portfolio now includes 14 patent filings, over 50 proprietary molecules, and 4 active drug programs targeting mental health disorders. CEO Doug Drysdale emphasized the ongoing development of the company's IP portfolio to enhance new discoveries in psychedelic therapeutics.
Cybin has announced the election of Theresa Firestone to its board of directors during a shareholder meeting on August 16, 2021. A total of 45,681,073 common shares were represented, accounting for 30.77% of total shares. Key voting results include the appointment of Zeifmans LLP as auditor with 99.76% approval, setting the board size at six directors with 99.87% approval, and amendments to the equity incentive plan with 95.43% support. Additionally, a shareholder rights plan was approved to protect shareholders during potential takeover bids.
Cybin Inc. (NEO:CYBN) reported its unaudited financial results for Q1 ended June 30, 2021. The company raised over C$120M, including C$34M in August 2021. Key highlights include becoming the first psychedelic company listed on NYSE American, initiating a digital therapeutics platform, scaling European operations, and expanding its patent portfolio to 13 filings. Cybin also commenced a collaboration with TMS NeuroHealth Centers to advance research in psychedelic therapeutics. The company reported a net loss of C$14.7 million for the quarter.
Summary not available.
Cybin Inc. (CYBN) announces that its subsidiary Adelia Therapeutics has met key milestones as stipulated in the December 2020 Transaction Agreement. Adelia will receive Class B common shares worth approximately CAD 475,292, which can be exchanged for Cybin common shares at a 10-to-1 ratio. The Class B shares will have a staggered exchange schedule, allowing only a portion to be converted before December 2023. This development illustrates Cybin's commitment to advancing psychedelic therapeutic solutions.
Cybin (NYSE:CYBN), a biotechnology company focused on psychedelic therapeutics, has announced that CEO Doug Drysdale will present virtually at Canaccord Genuity’s 41st Annual Growth Conference on August 10, 2021, at 3:30 PM ET. The presentation will be webcast live and available for playback for 90 days following the event. Cybin is dedicated to advancing psychedelic treatments for psychiatric disorders using innovative drug discovery and delivery methods. Forward-looking statements regarding their strategic branding, capital markets exposure, and drug development programs are included in the release.